Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.
These studies were performed to determine the effect of AD-472, an attenuated human herpes simplex virus (HSV) type 2 or HSV-2 glycoprotein D (gD) when combined with an adjuvant, GPI-0100, a semi-synthetic Quillaja Saponin analog in a genital HSV-2 infection in guinea pigs. While animals immunized with either vaccine had reduced clinical disease, GPI-0100 only improved the efficacy of gD and did not affect the efficacy of the live vaccine. Neither vaccine had any therapeutic effect if administered 24 h after viral infection.
University of Alabama at Birmingham, Department of Pediatrics, Birmingham, AL 35233-1711, USA. dquenell@uab.edu
Debra C
DC
Quenelle
Deborah J
DJ
Collins
Terri L
TL
Rice
Mark N
MN
Prichard
Dante J
DJ
Marciani
Earl R
ER
Kern
D000276:Adjuvants, Immunologic; D000818:Animals; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D006801:Humans; D012503:Saponins / Q000276:immunology*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
D000276:Adjuvants, Immunologic; C484998:GPI0100; D022301:Herpes Simplex Virus Vaccines; D012503:Saponins; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2